These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Immunotoxins in the treatment of hematologic malignancies. Kreitman RJ; Pastan I Curr Drug Targets; 2006 Oct; 7(10):1301-11. PubMed ID: 17073592 [TBL] [Abstract][Full Text] [Related]
45. Novel genetic immunotoxins and intracellular antibodies for cancer therapy. Chen SY; Marasco WA Semin Oncol; 1996 Feb; 23(1):148-53. PubMed ID: 8607024 [TBL] [Abstract][Full Text] [Related]
46. Manipulation of the intratumor infiltrate by anti-tumor antibody conjugates. Obrist R Biochim Biophys Acta; 1987 Jul; 907(2):175-90. PubMed ID: 3297156 [No Abstract] [Full Text] [Related]
47. Interleukin 2 enhances the efficiency of immunotoxins in the treatment of mice with ascitic tumors. Margineanu M; Marches R; Dima S; Cialacu V; Kozma E; Savi G; Stavri H; Badea E; Bancu A; Mota G Neoplasma; 1991; 38(6):633-8. PubMed ID: 1766487 [TBL] [Abstract][Full Text] [Related]
48. Immunotoxins for central nervous system malignancy. Youle RJ Semin Cancer Biol; 1996 Apr; 7(2):65-70. PubMed ID: 8740561 [TBL] [Abstract][Full Text] [Related]
49. Monoclonal antibodies: does sufficient selectivity to cancer cells exist for therapeutic application? Oldham RK J Biol Response Mod; 1987 Jun; 6(3):227-34. PubMed ID: 3298552 [No Abstract] [Full Text] [Related]
50. Current status of antibody-toxin conjugates for tumor therapy. Ramakrishnan S Targeted Diagn Ther; 1990; 3():189-213. PubMed ID: 2131010 [No Abstract] [Full Text] [Related]
51. Targeted delivery of toxins and enzymes by antibodies and growth factors. Houston LL Curr Opin Biotechnol; 1993 Dec; 4(6):739-44. PubMed ID: 7764474 [TBL] [Abstract][Full Text] [Related]
52. Vascular targeting--a new approach to the therapy of solid tumors. Burrows FJ; Thorpe PE Pharmacol Ther; 1994 Oct; 64(1):155-74. PubMed ID: 7846113 [TBL] [Abstract][Full Text] [Related]
53. [Cancer therapy by using bispecific antibody]. Azuma A; Niitani H; Okumura K Gan To Kagaku Ryoho; 1991 Aug; 18(10):1535-42. PubMed ID: 1872618 [TBL] [Abstract][Full Text] [Related]
55. Rational design of immunotoxins: current progress and future prospects. Wawrzynczak EJ Anticancer Drug Des; 1992 Oct; 7(5):427-41. PubMed ID: 1388633 [TBL] [Abstract][Full Text] [Related]
56. Systemic immunotoxin therapy of cancer: advances and prospects. Wawrzynczak EJ Br J Cancer; 1991 Oct; 64(4):624-30. PubMed ID: 1911210 [No Abstract] [Full Text] [Related]
58. General strategies in in vivo animal modeling. Vallera DA; Blazar BR Targeted Diagn Ther; 1992; 7():63-77. PubMed ID: 1633310 [No Abstract] [Full Text] [Related]
59. Rationale for clinical use of immunotoxins in cancer and autoimmune disease. Byers VS; Baldwin RW Semin Cell Biol; 1991 Feb; 2(1):59-70. PubMed ID: 1954344 [TBL] [Abstract][Full Text] [Related]
60. [Immunotoxin: from the idea of "magic bullets" to clinical applications]. Engert A; Thorpe P Med Klin (Munich); 1990 Sep; 85(9):555-60. PubMed ID: 2233614 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]